ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO923

Comparing Mortality and Morbidity of COVID-19 Omicron Variant vs. Other Variants in a Hemodialysis Population in Qatar

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Elgaali, Musab, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
  • Ali, Mohamed Yousif Mohamed Salih, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
  • Alkadi, Mohamad M., Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
  • Ibrahim, Rania Abdelaziz, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
  • Boubaker, Karima, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
  • Ismail, Hany Ezzat, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
  • Othman, Muftah, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
  • Al-Malki, Hassan A., Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
  • Hamad, Abdullah Ibrahim, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
Background

Patients on dialysis are more susceptible to COVID-19 infection, with higher mortality and morbidity. In December 2021 the state of Qatar witnessed a surge in COVID 19 cases solely due to omicron variant. We compare the effect of omicron Vs pre-omicron variants COVID infection on hemodialysis patients in terms of incidence, severity and mortality.

Methods

This is an observational, analytical, retrospective, nationwide study. COVID-19 PCR was the method of diagnosis. During the Omicron wave, Rapid Antigen Test was accepted by Ministry of Health in Qatar as a diagnostic test.
Our study followed patients for duration from 3/2020 to 1/2022. All positive results from 1st of December 2021 were assigned to the omicron group as per national genomic surveillance. Cases before that were assigned to the pre-omicron group. Primary outcome was to compare the incidence of omicron infections in haemodialysis patient compared to pre-omicron era. Secondary outcomes were to assess the mortality, ICU admissions, length of stay in ICU and need for ventilatory support in omicron vs pre-omicron phase. Patient demographics and clinical features were collected from a national electronic medical record.

Results

274 haemodialysis patients were diagnosed with COVID-19 during the omicron wave (2 months period) vs174 patients in the pre-omicron period (21 months). The incidence in omicron wave was 30.3%, which is significantly higher than pre-omicron waves of 18.7% (p <0.001). Omicron variant has lower mortality rate 2.4%, compared to other variants grouped together 15.5% (p <0.001).
ICU admissions rate during the omicron wave was significantly less than pre-omicron waves (4.9% Vs 26.4% (p <0.001)), and there was less need for ventilatory support (0.01% Vs 0.16% (p <0.001)). ICU length of stay was not significantly different (16.7+/-8 days Vs 14.2 +/- 17.5 days (p = 0.34)).

Conclusion

This is the 1st national study to compare the outcome of omicron vs non-omicron COVID-19 variants infection among hemodialysis patients. The incidence of omicron variant was higher than pre-omicron variants, while mortality and ICU admission were significantly lower in the omicron era compared to pre-omicron era. ICU length of stay was not significantly different.